Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isak W Tengesdal

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Immunology|June 13, 2022
IL-38 Gene Deletion Worsens Murine ColitisDennis M de Graaf, Ruth X Wang, Jesús Amo-Aparicio, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2016
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligoGiulio Cavalli, Masahiro Hayashi, Ying Jin, et al.
The Journal of Biological Chemistry|July 15, 2018
Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissueDov B Ballak, Suzhao Li, Giulio Cavalli, et al.
The Lancet. Rheumatology|October 2, 2020
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trialViola Klück, Tim L Th A Jansen, Matthijs Janssen, et al.
Cell Reports|April 7, 2021
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunityGiulio Cavalli, Isak W Tengesdal, Mark Gresnigt, et al.
Nature Immunology|March 19, 2024
International nomenclature guidelines for the IL-1 family of cytokines and receptorsJoseph M Gaballa, Jesper Falkesgaard Højen, Dennis M De Graaf, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2021
Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansionIsak W Tengesdal, Dinoop R Menon, Douglas G Osborne, et al.
Blood|June 2, 2021
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester diseaseRaffaella Molteni, Riccardo Biavasco, Davide Stefanoni, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Somatic mutations reveal the ontogeny of human microgliaJulia A Belk, Yaowen Zhang, Quanming Shi, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Frontiers in Immunology|June 13, 2022
IL-38 Gene Deletion Worsens Murine ColitisDennis M de Graaf, Ruth X Wang, Jesús Amo-Aparicio, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 21, 2016
MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligoGiulio Cavalli, Masahiro Hayashi, Ying Jin, et al.
The Journal of Biological Chemistry|July 15, 2018
Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissueDov B Ballak, Suzhao Li, Giulio Cavalli, et al.
The Lancet. Rheumatology|October 2, 2020
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trialViola Klück, Tim L Th A Jansen, Matthijs Janssen, et al.
Cell Reports|April 7, 2021
The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunityGiulio Cavalli, Isak W Tengesdal, Mark Gresnigt, et al.
Nature Immunology|March 19, 2024
International nomenclature guidelines for the IL-1 family of cytokines and receptorsJoseph M Gaballa, Jesper Falkesgaard Højen, Dennis M De Graaf, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 2, 2021
Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansionIsak W Tengesdal, Dinoop R Menon, Douglas G Osborne, et al.
Blood|June 2, 2021
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester diseaseRaffaella Molteni, Riccardo Biavasco, Davide Stefanoni, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Somatic mutations reveal the ontogeny of human microgliaJulia A Belk, Yaowen Zhang, Quanming Shi, et al.
Pageof 2